Akiva Felt Recent News
Oppenheimer: Teva Is Now Worth $77/Share, More Deals To Come
UPDATE: Oppenheimer Upgrades Zogenix Following Zohydro Approval
UPDATE: Oppenheimer Initiates Coverage on Cubist Pharmaceuticals on Strong Antibiotic Portfolio
Oppenheimer Reiterates Perform Rating on Amarin Following AMR-102 Study
UPDATE: Oppenheimer Assumes Zogenix at Perform on Fair Valuation
UPDATE: Oppenheimer Assumes Viropharma at Outperform on Expected Improvement Ahead
UPDATE: Oppenheimer Assumes Antares Pharma at Outperform on Multiple Positive Factors
UPDATE: Oppenheimer Assumes Endo Health Solutions at Perform on Operational Restructuring
UPDATE: Oppenheimer Initiates Amarin at Perform on Vascepa Potential
UPDATE: Oppenheimer Initiates Intercept Pharmaceuticals at Outperform on Bullish Outlook
UPDATE: Oppenheimer Assumes Medicines Company at Perform Rating on Valuation
UPDATE: Oppenheimer Assumes Questcor Pharmaceuticals at Outperform on Compelling Upside Potential